Caffo Nathan 4
4 · ALX ONCOLOGY HOLDINGS INC · Filed Jul 21, 2020
Insider Transaction Report
Form 4
Caffo Nathan
Chief Business Officer
Transactions
- Conversion
Common Stock
2020-07-21+10,529→ 11,254 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2020-07-21−10,529→ 0 total(indirect: See footnote)→ Common Stock (10,529 underlying)
Footnotes (3)
- [F1]Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- [F2]Includes 725 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.
- [F3]The shares are held of record by the reporting person's spouse.